Local immunosuppression induced by high viral load of human papillomavirus: Characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions

Immunology

Volumn 146, Issue 1, 2015, Pages 113-121

  Prata, Thiago Theodoro Martins ^a   Bonin, Camila Mareti ^a   Ferreira, Alda Maria Teixeira ^a   Padovani, Cacilda Tezelli Junqueira ^a   Fernandes, Carlos Eurico dos Santos ^a   Machado, Ana Paula ^a   Tozetti, Inês Aparecida ^a  

^a FEDERAL UNIVERSITY OF MATO GROSSO DO SUL   (Brazil)

Author keywords

Human papillomavirus; Immunosuppression; Interleukin 10

Indexed keywords

INTERLEUKIN 10; TRANSCRIPTION FACTOR FOXP3; IL10 PROTEIN, HUMAN;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LANGERHANS CELL; MACROPHAGE; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LOAD; WART VIRUS; ADOLESCENT; AGING; BIOSYNTHESIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; UTERINE CERVIX TUMOR; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGING; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; KERATINOCYTES; LANGERHANS CELLS; MACROPHAGES; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; TUMOR MICROENVIRONMENT; UTERINE CERVICAL NEOPLASMS; VIRAL LOAD; YOUNG ADULT;

EID: 84938417172     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12487     Document Type: Article

References (50)

1. Ferlay JI, Soerjomataram M, Ervik R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2013; 136:E359-86.
2. Bosch FX, Manos MM, Muñoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802.
3. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
4. Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24Suppl3:S3/1-10.
5. Madeleine MM, Brumback B, Cushing-Haugen KL et al. Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis 2002; 186:1565-74.
6. Nardelli-Haefliger D, Wirthner D, Schiller JT, Lowy DR, Hildesheim A, Ponci F, De Grandi P. Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles. J Natl Cancer Inst 2003; 95:1128-37.
7. Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808-16.
8. García-Closas R, Castellsagué X, Bosch X, González CA. The role of diet and nutrition in cervical carcinogenesis: a review of recent evidence. Int J Cancer 2005; 117:629-37.
9. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32suppl1:S16-24.
10. Isabel Domínguez-Castillo R, Sánchez-Guzmán E, Castro-Muñozledo F, Santos-Argumedo L, Kuri-Harcuch W. Epidermal keratinocytes do not activate peripheral T-cells: interleukin-10 as a possible regulator. Immunology 2008; 125:370-6.
11. Torres-Poveda K, Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH, Peralta-Zaragoza O, Madrid-Marina V. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol 2014; 5:753-63.
12. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 2001; 75:4283-96.
13. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol 2008; 1:412-20.
14. Mindiola R, Caulejas D, Núñez-Troconis J, Araujo M, Delgado M, Mosquera J. Increased number of IL-2, IL-2 receptor and IL-10 positive cells in premalignant lesions of the cervix. Invest Clin 2008; 49:533-45.
15. Bermudez-Morales VH, Gutierrez LX, Alcocer-Gonzalez JM, Burguete A, Madrid-Marina V. Correlation between IL-10 gene expression and HPV infection in cervical cancer: a mechanism for immune response escape. Cancer Invest 2008; 26:1037-43.
16. Bermúdez-Morales VH, Peralta-Zaragoza O, Alcocer-González JM, Moreno J, Madrid-Marina V. IL-10 expression is regulated by HPV E2 protein in cervical cancer cells. Mol Med Rep 2011; 4:369-75.
17. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity and transplantation tolerance. Immunol Rev 2001; 182:18-32.
18. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. The dual role of IL-10. Trends Immunol 2003; 24:36-43.
19. Bernard HU, Chan SY, Manos MM et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994; 170:1077-85.
20. International Agency for Research on Cancer (IARC). Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomaviruses. Lyon, France: IARC, 2007.
21. Köllisch G, Kalali BN, Voelcker V et al. Various members of the Toll-like receptor family contribute to the innate immune response of human epidermal keratinocytes. Immunology 2005; 114:531-41.
22. Mota F, Rayment N, Chong S, Singer A, Chain B. The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol 1999; 116:33-40.
23. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001; 23:291-9.
24. Castellsagué X, Díaz M, de Sanjosé S et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98:303-15.
25. Flores R, Papenfuss M, Klimecki WT, Giuliano AR. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. Int J Cancer 2006; 118:1187-93.
26. Gravitt PE, Kovacic MB, Herrero R et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int J Cancer 2007; 121:2787-93.
27. Lo KW, Yeung SW, Cheung TH, Siu NS, Kahn T, Wong YF. Quantitative analysis of human papillomavirus type 16 in cervical neoplasm: a study in Chinese population. J Clin Virol 2005; 34:76-80.
28. Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol 1999; 42:93-106.
29. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-8.
30. Alcocer-González JM, Berumen J, Taméz-Guerra R et al. In vivo expression of immunosuppressive cytokines in human papillomavirus-transformed cervical cancer cells. Viral Immunol 2006; 19:481-91.
31. Giannini SL, Hubert P, Doyen J, Boniver J, Delvenne P. Influence of the mucosal epithelium microenvironment on Langerhans cells: implications for the development of squamous intraepithelial lesions of the cervix. Int J Cancer 2002; 97:654-9.
32. Jacobs N, Renard I, Al-Saleh W, Hubert P, Doyen J, Kedzia W, Boniver J, Delvenne P. Distinct T cell subsets and cytokine production in cultures derived from transformation zone and squamous intraepithelial lesion biopsies of the uterine cervix. Am J Reprod Immunol 2003; 49:6-13.
33. Bhairavabhotla RK, Verm V, Tongaonkar H, Shastri S, Dinshaw K, Chiplunkar S. Role of IL-10 in immune suppression in cervical cancer. Indian J Biochem Biophys 2007; 44:350-6.
34. Syrjänen S, Naud P, Sarian L et al. Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort. Virchows Arch 2009; 455:505-15.
35. Chaperot L, Plumas J, Jacob MC, Bost F, Molens JP, Sotto JJ, Bensa JC. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp Hematol 1999; 27:479-88.
36. Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. Identification of the α6 integrin as a candidate receptor for papillomaviruses. J Virol 1997; 71:2449-56.
37. Jimenez-Flores R, Mendez-Cruz R, Ojeda-Ortiz J et al. High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology 2006; 117:220-8.
38. Pasare C, Medzhitov R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004; 21:733-41.
39. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcγ receptors and contributes to acquisition of T cell immunity. J Immunol 2007; 178:7587-97.
40. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J Immunol 2002; 169:3242-9.
41. Kobayashi A, Greenblatt RM, Anastos K et al. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res 2004; 64:6766-74.
42. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114:280-90.
43. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18:605-17.
44. + T cells. J Immunol 2010; 184:1765-75.
45. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389:737-42.
46. Bolpetti A, Silva JS, Villa LL, Lepique AP. Interleukin-10 production by tumor infiltrating macrophages plays a role in Human Papillomavirus 16 tumor growth. BMC Immunol 2010; 11:27.
47. + regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice. PLoS ONE 2011; 6:e19495.
48. Mei J, Xie XX, Li MQ, Wei CY, Jin LP, Li DJ, Zhu XY. Indoleamine 2, 3-dioxygenase-1 (IDO1) in human endometrial stromal cells induces macrophage tolerance through interleukin-33 in the progression of endometriosis. Int J Clin Exp Pathol 2014; 7:2743-57.
49. 1 promoter throughout Sp1 recognition sequence. Viral Immunol 2006; 3:468-80.
50. Montesinos JJ, Mora-Garcia ML, Mayani H et al. In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity. Stem Cells Dev 2013; 22:2508-19.